KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BeOne Medicines (ONC) FCF Margin (2016 - 2025)

BeOne Medicines (ONC) has disclosed FCF Margin for 11 consecutive years, with 27.51% as the latest value for Q4 2025.

  • On a quarterly basis, FCF Margin rose 2040.0% to 27.51% in Q4 2025 year-over-year; TTM through Dec 2025 was 20.03%, a 2408.0% increase, with the full-year FY2025 number at 20.03%, up 2557.0% from a year prior.
  • FCF Margin was 27.51% for Q4 2025 at BeOne Medicines, down from 28.92% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 103.68% in Q4 2021 to a low of 297.81% in Q3 2021.
  • A 5-year average of 61.02% and a median of 48.24% in 2023 define the central range for FCF Margin.
  • Peak YoY movement for FCF Margin: skyrocketed 72312bps in 2021, then crashed -21932bps in 2022.
  • BeOne Medicines' FCF Margin stood at 103.68% in 2021, then crashed by -212bps to 115.64% in 2022, then surged by 48bps to 59.68% in 2023, then skyrocketed by 112bps to 7.11% in 2024, then surged by 287bps to 27.51% in 2025.
  • Per Business Quant, the three most recent readings for ONC's FCF Margin are 27.51% (Q4 2025), 28.92% (Q3 2025), and 20.2% (Q2 2025).